Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (401-410 of 436) with videos related to

Pageof 44
Sort By:
American Journal of Hematology|October 20, 2017
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphomaYasmin Abaza, Hagop M Kantarjian, Stefan Faderl, et al.
Haematologica|February 16, 2015
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemiaMarina Konopleva, Peter F Thall, Cecilia Arana Yi, et al.
Blood|May 5, 2022
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasmsAdam S Sperling, Veronica A Guerra, James A Kennedy, et al.
Cancer Discovery|November 10, 2018
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Guillermo Garcia-Manero, Sreyashi Basu, et al.
Cancer|August 7, 2025
Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemiaJayastu Senapati, Hagop M Kantarjian, Tapan M Kadia, et al.
JCO Precision Oncology|December 10, 2025
Clinical Outcomes of Adult Patients With Newly Diagnosed Mixed Phenotype Acute LeukemiaHannah Goulart, Farhad Ravandi, Nicholas J Short, et al.
American Journal of Hematology|September 2, 2022
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatmentCurtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
Blood Cancer Discovery|March 8, 2021
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitorsAhmad S Alotaibi, Musa Yilmaz, Rashmi Kanagal-Shamanna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2018
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid LeukemiaKiyomi Morita, Hagop M Kantarjian, Feng Wang, et al.
Blood|September 7, 2018
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosisLucia Masarova, Srdan Verstovsek, Juliana E Hidalgo-Lopez, et al.
Pageof 44

Showing results (401-410 of 436) with videos related to

Sort By:
Pageof 44
American Journal of Hematology|October 20, 2017
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphomaYasmin Abaza, Hagop M Kantarjian, Stefan Faderl, et al.
Haematologica|February 16, 2015
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemiaMarina Konopleva, Peter F Thall, Cecilia Arana Yi, et al.
Blood|May 5, 2022
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasmsAdam S Sperling, Veronica A Guerra, James A Kennedy, et al.
Cancer Discovery|November 10, 2018
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II StudyNaval Daver, Guillermo Garcia-Manero, Sreyashi Basu, et al.
Cancer|August 7, 2025
Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemiaJayastu Senapati, Hagop M Kantarjian, Tapan M Kadia, et al.
JCO Precision Oncology|December 10, 2025
Clinical Outcomes of Adult Patients With Newly Diagnosed Mixed Phenotype Acute LeukemiaHannah Goulart, Farhad Ravandi, Nicholas J Short, et al.
American Journal of Hematology|September 2, 2022
Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatmentCurtis A Lachowiez, Patrick K Reville, Hagop Kantarjian, et al.
Blood Cancer Discovery|March 8, 2021
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitorsAhmad S Alotaibi, Musa Yilmaz, Rashmi Kanagal-Shamanna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2018
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid LeukemiaKiyomi Morita, Hagop M Kantarjian, Feng Wang, et al.
Blood|September 7, 2018
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosisLucia Masarova, Srdan Verstovsek, Juliana E Hidalgo-Lopez, et al.
Pageof 44